Introduction: Immunotherapy targeting the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint has shown promising efficacy in patients with NSCLC. Lymphocyte activating 3 gene (LAG-3) is another important checkpoint, and its role in NSCLC is still not clear. In this study we investigated lymphocyte activing 3 (LAG-3) protein expression; its correlation with PD-1, PD-L1, and tumor-infiltrating lymphocytes (TILs); and its association with survival in NSCLC.
PD-L1-and LAG-3-positive (2. . In the verification stage, high expression of LAG-3 was also significantly correlated with higher expression of PD-1 on TILs (p ¼ 0.016) and PD-L1 on tumor cells (p ¼ 0.014). There was no correlation between LAG-3 expression and EGFR (p ¼ 0.325) and KRAS mutation (p ¼ 1.000) and ALK fusion (p ¼ 0.562).
Introduction
The incidence of lung cancer around the world is increasing. 1 Of these cases, about 80% are NSCLC and most are diagnosed at an advanced stage. 2 Chemotherapy as a standard first-line therapy has a poor prognosis. Although targeted therapy shows promise in the treatment of advanced NSCLC, [3] [4] [5] only the small population that harbors driving mutations such as EGFR can get benefit. 6, 7 Moreover, acquired resistance to targeted drugs remains a major hurdle, limiting their ability to prolong survival. 5 Therefore, it remains urgent to find new, more effective therapeutic strategies for patients with advanced NSCLC.
Immunotherapy can reverse tumor immune escape by suppressing immune checkpoints, and it was regarded as one of the most important scientific breakthroughs in 2013. 8 The inhibition of cytotoxic T lymphocyte antigen 4 (CTLA4), programmed death 1 (PD-1), and programmed death ligand 1 (PD-L1) among others can activate T cells to eliminate tumors. [9] [10] [11] [12] [13] [14] Recently, anti-PD-1 or anti-PD-L1 antibodies have shown promising efficacy in melanoma, renal, lung and other cancers. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Significantly, nivolumab and pembolizumab have been approved by the U.S. Food and Drug Administration as second-line treatments for advanced NSCLC on the basis of the Checkmate 017 and Keynote 010 trials, etc. 15, 26 However, less than 25 percent of patients are expected to benefit from anti-PD-1/PD-L1 therapy, highlighting the necessity of further investigation into other strategies such as simultaneous inhibition.
Lymphocyte activating gene 3 (LAG-3) (CD 223) is another important checkpoint belonging to the immunoglobulin superfamily and may have a synergistic effect with PD-1/PD-L1. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] It could affect T-cell function. 47 LAG-3 is expressed on natural killer cells, 46 B cells, 47 tumor-infiltrating lymphocytes (TILs), a subset of T cells, 48 and dendritic cells' membranes. 49, 50 LAG-3 has a close relationship with CD4 41 and shares about 20% of its DNA sequence. 46 LAG-3 is embedded in the CD4 locus and encodes a protein that binds a nonholomorphic region of major histocompatibility complex II (MHC class II) with greater affinity than CD4.
51-57 LAG-3 inhibits T-cell proliferation, activation, and homeostasis and may have synergistic effects with PD-1 and PD-L1. 44, [58] [59] [60] However, lymphocyte activating 3 (LAG-3) protein expression in NSCLC and the relationship between LAG-3 and PD-1/PD-L1 have not been analyzed. In this study, we investigated LAG-3 protein expression in NSCLC cell lines and patients with NSCLC by immunohistochemistry (IHC) and analyzed the relationship between LAG-3 and clinicopathological traits. We also analyzed its correlation with PD-1, PD-L1, and TILs and conducted survival analysis of patients with NSCLC.
Patients and Methods

Patients
Primary tumor specimens were obtained from 139 surgical patients with NSCLC at the Department of Oncology and Radiotherapy, Medical University of Gdansk, in Gdansk, Poland, from April 2008 to August 2010. The patients had not undergone radiotherapy or chemotherapy before surgery. The surgical histology reports were reviewed and the lymph node and lung cancer stages were categorized according to the seventh edition of the International Association for the Study of Lung Cancer TNM staging system. Approval to conduct this study was obtained from the Shanghai Pulmonary Hospital, Tongji University (ethical number , in accordance with the guidelines of the Helsinki Declaration of 1975, as revised in 1983. All participants were competent to provide their consent in the Medical University of Gdansk.
Cell Lines
A tissue microarray (TMA) (2 mm) containing 55 NSCLC cell lines was produced in the Hirsch Laboratory, and all samples were triplicated. Cells were harvested, fixed overnight, mixed with 0.9% agarose, and then allowed to solidify at room temperature for at least 5 minutes. Each solidified agar pellet was gently placed in a cassette and submerged in 70% ethyl alcohol. The pellets were processed and embedded in paraffin blocks. Cores were taken from each cell line block to create the TMA, from which 4-mm sections were cut.
IHC for LAG-3 and PD-1 by Ventana Benchmark XT Paraffin-embedded tissue sections were baked in a drying oven at 60 C for 1 hour. Heat-mediated antigen retrieval was performed on LAG-3 slides. ) was applied, and the slides were incubated at 37 C for 1 hour. An UltraView DAB detection and amplification kit (Ventana Medical Systems) was used. Slides were counterstained with hematoxylin for 4 minutes and postcounterstained with bluing agent for 4 minutes. Slides were washed and then dehydrated in 70% to 100% reagent alcohol baths and then in xylene baths before application of the coverslips. We used human tonsil as the positive control for LAG-3 and PD-1.
IHC for PD-L1 by Dako
Paraffin tissue sections were baked in a drying oven at 60 C for 1 hour. Slides were loaded onto a Dako autostainer (Dako, Carpenteria, CA) and treated with proteinase K for 5 minutes. Primary antibody (PD-L1, 22C3 [Dako]) was applied by the Dako autostainer, and the slides were then incubated at room temperature for 30 minutes. After a wash in buffer, slides were incubated with a labeled polymer (horseradish peroxidase) at room temperature for 30 minutes. Next, diaminobenzidine-positive substratechromagen solution was applied for 10 minutes. Slides were counterstained with Dako automation hematoxylin for 5 minutes and postcounterstained with bluing agent for 1 minute. Slides were washed and then dehydrated in three washes of 70%, 95%, and 100% reagent alcohol and then in three xylene baths before application of the coverslips. Negative and positive controls were provided with the Dako kits.
Determination of LAG-3, PD-1, and PD-L1 IHC Cutoff
All IHC results were checked independently by two pathologists (H.Y. and L.H.). As our LAG-3 cutoff, we chose a value of more than 20%, as it was the best value to predict both recurrence-free survival (RFS) and overall survival (OS). The cutoff for PD-1 was at least 8% staining according to the former publication. 61 The cutoff for PD-L1 on tumor cells (approved by U.S. Food and Drug Administration) was at least 50% staining.
Evaluation of TILs
We calculated the number of lymphocytes in the microscope's field of vision on hematoxylin-stained sections, as described. 62 The infiltrating intensity of TILs was assessed with a semiquantitative score from 1þ to 3þ, with a score of 1þ (<30%) indicating a low percentage of TILs, 2þ indicating a moderate percentage (30%-60%), and 3þ indicating a marked (>60%) increase in TILs. The TILs were composed of mononuclear cells, including lymphocytes, macrophages and plasma cells. Intraalveolar macrophages were not considered as part of the immune infiltration. Spots with discordance in TIL category between pathologists were reviewed jointly and a single consensus category was established. 63 
Verification of the Results
To verify the results, we detected LAG-3, PD-1, and PD-L1 in 62 samples from patients with NSCLC from the Dan Laboratory (University of Colorado). All patients had newly diagnosed NSCLC. The patients had not undergone radiation or chemotherapy before the biopsy. To check the correlation between checkpoints and driver mutations, we also detected mutations in EGFR and KRAS and rearrangements of echinoderm microtubule associated protein like 4 gene (EML4)-anaplastic lymphoma receptor tyrosine kinase gene (ALK). DNA and the total RNA were immediately extracted from fresh tissues by using a commercial QIAamp DNA Tissue Kit and RNeasy Kit (Qiagen, Hilden, Germany), respectively. Mutations in the EGFR and KRAS genes and the rearrangement of EML4-ALK were detected with Amoy Diagnostics kits (Amoy Diagnostics, Xiamen, China) by utilizing proprietary real-time polymerase chain reaction technology to detect mutations in the target genes.
Statistical Analysis
We performed statistical analysis with SPSS 17.0 software (SPSS, Inc., Chicago, IL). Chi-square tests were used to analyze the correlation between LAG-3 protein expression and clinicopathological variables, PD-1, PD-L1, TILs, and driver mutations. The correlation between the expression of LAG-3 and PD-1, PD-L1, and TILs was analyzed by Spearman's rank correlation. The ORs for positive LAG-3 expression were calculated by a logistic regression model for the factors age, sex, smoking status, pathological type, lung cancer stage, PD-1 in TILs, and PD-L1 in tumor cells. The survival curves were estimated by the Kaplan-Meier method. We used the Cox regression model to investigate the relationships between the correlative factors age, sex, smoking status, lung cancer stage, LAG-3 in TILs, PD-1 in TILs, and PD-L1 in tumor cells and RFS as well as OS. All statistics were two sided, and statistical significance was defined as p less than 0.05.
Results
LAG-3 in NSCLC Cell Lines
LAG-3 expression was not detected in any of the 55 NSCLC cell lines in the Hirsch laboratory TMA. (Fig. 1) .
Patient Characteristics
Of the 139 patients, 109 (78.4%) were male and 30 (21.6%) were female. The median age was 64 years. Six (4.3%) were never-smokers. The range of lung cancer stages was broad: 58 patients (41.7%) were stage I, 35 (25.2%) were stage II, 39 (28.1%) were stage III, and seven (5.0%) were stage IV. Forty patients (28.8%) had adenocarcinoma and 81 (58.3%) had squamous cell carcinoma ( Table 1) .
Characterization of LAG-3, PD-1, PD-L1, and TILs in NSCLC and Their Association with Clinicopathological Factors
Staining by IHC demonstrated expression of LAG-3, PD-1, and PD-L1 in the cell membranes. The results of testing for LAG-3 expression on the TILs were positive in 36 patients (25.9%). Sixty samples (43.2%) stained positive for PD-1 on the TILs, and 25 (18.0%) had positive PD-L1 expression on tumor cells (see Fig. 1 and Supplementary Table 1) . Evaluation of TILs found that 45% of samples had a score of 1þ (<30%), 27% had a score of 2þ (30%-60%), and 28% had a score of 3þ (>60%). Neither LAG-3 nor PD-1 was expressed on tumor cells. LAG-3 expression was higher in nonadenocarcinoma than in adenocarcinoma (p ¼ 0.031) (Supplementary Table 2 ). Neither the expression of PD-1 on TILs nor the expression of PD-L1 on tumor cells had a significant correlation with clinicopathological factors.
Relationship between Checkpoints and TIL Abundance
There was a correlation between the percentage of LAG-3 and PD-1-positive TILs (
. We also performed correlation analysis between LAG-3 and PD-L1 on TILs (R 2 ¼0.050, y ¼1.242x þ 13.399 [p < 0.001]) and between LAG-3 and TIL percentage (
High expression of LAG-3 was significantly correlated with higher expression of PD-1 on TILs (p < 0.001) and PD-L1 on tumor cells (p ¼ 0.041). The same relationship was not found between LAG-3 and TIL expression (p ¼ 0.244) ( Table 2) . We also used a value of at least 1% as the cutoff of PD-L1 on tumor cells and found that high expression of LAG-3 was still significantly correlated with higher expression of PD-L1 on tumor cells (p ¼ 0.006).
Univariate and Multivariate Logistic Analysis for Predicting LAG-3 Expression
With the logistic regression model, the ORs for LAG-3 were 0.320 (95% CI: 0.110-0.929) and 4.364 (95% CI: 1.898-10.031) when nonadenocarcinoma was compared 
(PD-L1) (Â20). (A) LAG-3-negative expression on an NSCLC cell line (H520) (Â20). (B) IHC positivity for LAG-3 on tumor-infiltrating lymphocytes (TILs). (C) IHC positivity for PD-1 on tumor-infiltrating lymphocytes (TILs). (D) IHC positivity for PD-L1 on a tumor cell.
with adenocarcinoma and when TILs negative for PD-1 were compared with those positive for PD-1 (Table 3) .
Association between LAG-3, PD-1, and PD-L1 and RFS and OS in Patients with NSCLC RFS was significantly different in patients whose TILs were LAG-3-negative as opposed to LAG-3-positive (Fig. 2) . Tables 3 and 4) .
Cox Regression Analysis of RFS and OS
Verification of the Results
The results of testing for LAG-3 expression on the TILs were positive in 16 patients (25.8%). Twenty-five samples (40.3%) stained positive for PD-1 on the TILs, and 15 (24.2%) had positive PD-L1 expression on tumor cells (Supplementary Table 5 ). Six (9.7%) patients tested positive for EGFR mutation, four (6.5%) had KRAS mutation, and three (4.8%) had ALK fusion. High expression of LAG-3 was significantly correlated with higher expression of PD-1 on TILs (p ¼ 0.016) and PD-L1 on tumor cells (p ¼ 0.014). There was no correlation between LAG-3 expression and EGFR (p ¼ 0.325) and KRAS mutation (p ¼ 1.000) and ALK fusion (p ¼ 0.562) in these patients. 
Discussion
To our knowledge, this is the first study to analyze LAG-3 protein expression in NSCLC cell lines and patients and to describe the correlations between LAG-3 and PD-1, PD-L1, and TILs.
LAG-3 has been researched in many contexts, including hematopoietic malignancies and solid tumors. 64 Studies indicate that LAG-3 could suppress anticancer immunity in Hodgkin's lymphoma. 65 It was reported that anti-LAG-3 therapy might control breast cancer in a mouse model. 37 Inhibiting the LAG-3 and PD-1 pathways could improve T-cell function in ovarian cancer. 66 In hepatocellular carcinoma, elevated expression of LAG-3 on TILs has been observed. 67 In gastric cancer, positive PD-1 and LAG-3 expression was elevated on CD4-positive and CD8-positive T cells, which might impair cell-mediated immunity after surgery. 60 It has been postulated that LAG-3/MHC class II interaction in MHC class II-positive melanoma tumors might serve as a bidirectional immune escape pathway shared by tumor cells and immune cells. 43 Additionally, there is a possibility that soluble LAG-3 could be harnessed as a cancer vaccine. [68] [69] [70] [71] LAG-3 is a promising target, perhaps more so than CTLA4 or PD-1/ PD-L1, because anti-LAG-3 antibodies can activate both T effector cells and regulatory T cells, whereas anti-CTLA4, anti-PD-1, and anti-PD-L1 antibodies do not improve the activity of regulatory T cells. 72 Numerous companies are focusing on LAG-3 and many approaches involving it are in clinical development, including soluble LAG-3 (Immutep, Orsay, France) and anti-LAG-3 (BristolMyers Squibb, Lawrenceville, NJ, and GlaxoSmithKline, Research Triangle Park, NC).
Despite the many ongoing LAG-3-related clinical trials, data on LAG-3 expression in NSCLC are lacking. In this study, we stained LAG-3 in NSCLC cell lines and NSCLC tumor tissues. We found that LAG-3 was not expressed on NSCLC cell lines and that in tumor cells it was expressed only on TILs. LAG-3 expression on TILs was greater in nonadenocarcinoma than in adenocarcinoma. Given the scarcity of biomarkers for squamous cell carcinoma relative to lung adenocarcinoma, the potential for LAG-3 as a biomarker for nonadenocarcinoma, as indicated by our results, is notable.
Further, we analyzed the correlation between LAG 3 and PD-1, PD-L1, and TILs and found that LAG-3 expression was correlated with expression of PD-1 on TILs and expression of PD-L1 on tumor cells. Higher expression of LAG-3 on TILs was significantly correlated with higher expression of PD-1 on TILs and higher expression of PD-L1 on tumor cells. Our findings correlating LAG-3 with PD-1 and PD-L1 are supported by and build upon a significant body of research linking these three checkpoints. It is reported that LAG-3 may have synergistic action with PD-1/PD-L1. 45, 59, 73 Both LAG-3 and PD-1 regulate autoimmunity, and they synergistically prevent autoimmunity. 44 In vivo research showed that blockade of either PD-1 or LAG-3 pathways could activate T cells, and the blockade of both pathways had a greater effect than blockade of either alone. 36 LAG-3 and PD-1 may affect both antigen and cytokine signaling and inhibit CD8 T cells. 35 In ovarian cancer, it has been reported that LAG-3 and PD-1 could down-regulate CD8-positive TILs. 74 It was also demonstrated that LAG-3 and PD-1 synergistically inhibited T-cell function and antitumor immune response. 45 In our study, we also found that LAG-3 expression correlated with expression of PD-1 and PD-L1.
We also conducted survival analysis for RFS and OS. LAG-3 was related to poor prognosis. LAG-3 positivity or both LAG-3 and PD-L1 positivity was correlated with early postoperative recurrence. This was consistent with previously reported results. In chronic lymphocytic leukemia, LAG-3 was as a novel prognostic marker: higher expression of LAG-3 was correlated with shorter treatment-free survival. 75 In a transplantable tumor mouse model involving dual knockout mice, dual anti-LAG-3/anti-PD-1 antibody treatment markedly increased survival. Blockade of both molecules could be a promising combinatorial strategy for cancer. 45 There are some limitations in our study. First, it is a retrospective study in which we lacked some data, including driver mutation status. Second, previous research had not established the cutoff for determination of positive LAG-3 protein expression by IHC, nor was one provided by Abcam. So we used what we determined to be the best point for predicting both RFS and OS. Third, the population of this study was not large. A prospective study and a large cohort of patients with NSCLC are needed.
In conclusion, immune checkpoints are crucial to tumor immune escape. However, the synergistic interactions between various immune checkpoints are not yet understood. CTLA4-, PD-1-, and PD-L1-related treatments in patients with cancer have had remarkable effects. LAG-3 is another important immune checkpoint whose synergistic function requires further exploration. In this study, we found a clinical correlation between LAG-3 and PD-1 and between LAG-3 and PD-L1. LAG-3 positivity or both LAG-3 and PD-L1 positivity was correlated with early postoperative recurrence. LAG-3 was related to poor prognosis. Further, analysis of the molecular mechanism of the synergistic effect of LAG-3 with PD-1 and PD-L1 in NSCLC needs to be conducted. 
